从分子病理看结直肠癌精准医学的机遇与挑战1 2021/5/7目 录 精准医学时代下的CRC诊疗 CRC中分子标记物及其临床意义 未来CRC精确诊断的方向-体液2 2021/5/7GLOBOCAN 2012：Estimated Cancer Incidence,Mortality and Prevalence Worldwide in 20123 2021/5/71980 1985 1990 1995 2000 2005 2010Median OS5-FUIrinotecanCapecitabineOxaliplatinCetuximabBevacizumabPanitumumabOS (Mos)30201001980 1985 1990 1995 2000 2005Yr2010Ziv-afliberceptRegorafenibChanging 5-Year Survival Expectations in the United States for GI Cancers(1975-1977 v 2003-2009 )5-Year Survival(%)Cancer Site 1975
